Shareholders to Vote on Massive Potential Dilution from CEO Performance Warrants and Related-Party Acquisitions
Summary
ZenaTech shareholders will vote on proposals that include a new CEO compensation package with warrants for up to 115.5 million common equivalent shares and two related-party acquisitions totaling $36 million, collectively representing massive potential dilution.
Key Events
-
Massive Potential Dilution from CEO Performance Warrants
Shareholders are asked to approve an Amended CEO Employment Agreement granting Dr. Shaun Passley performance warrants for up to 38.5 million Preferred Shares and 825,000 Super Voting Shares. If all Preferred Share Warrants were exercised and converted, this alone could result in 115.5 million new common equivalent shares, representing approximately 132% of current outstanding common shares.
-
Significant Related-Party Acquisitions Approved for Share Issuance
The company proposes two related-party acquisitions from Epazz (controlled by the CEO) totaling $36 million. These acquisitions, including IQ Drone Technology, Provitrac Technology, and K9 Sky Shares, would be paid for by issuing 10.43 million common shares and 1.11 million Preferred Shares (equivalent to 3.32 million common shares), totaling 13.75 million common equivalent shares.
-
Amended Management Services Agreement with Related Party
An Amended and Restated Management Services Agreement with Epazz (a related party) formalizes services at cost plus a 20% markup. Payment will be 70% by reducing outstanding inter-company advances (CAD $22.45 million as of Dec 31, 2025) and 30% in cash, providing a structured mechanism for debt repayment.
-
Shareholder Meeting to Vote on Proposals
An Annual and Special Meeting is scheduled for July 14, 2026, where shareholders will vote on these and other routine matters, including the re-election of directors, appointment of auditors, and ratification of the Long-Term Incentive Plan.
Analysis
This filing outlines proposals for the upcoming Annual and Special Meeting, including several highly dilutive related-party transactions. Shareholders are asked to approve an Amended CEO Employment Agreement that could grant Dr. Shaun Passley (CEO) performance warrants convertible into up to 115.5 million common equivalent shares, representing approximately 132% of the current outstanding common shares. Additionally, two related-party acquisitions from Epazz (also controlled by Dr. Passley) totaling $36 million would result in the issuance of 13.75 million common equivalent shares. These proposals, if approved, represent a potential dilution of nearly 148% to existing common shareholders from new issuances alone. While the Amended Management Services Agreement provides a structured repayment plan for a significant inter-company receivable, the sheer scale of potential dilution from the CEO's compensation and the related-party acquisitions, which collectively exceed the company's current market capitalization, raises substantial concerns about shareholder value.
At the time of this filing, ZENA was trading at $1.42 on NASDAQ in the Technology sector, with a market capitalization of approximately $122.2M. The 52-week trading range was $1.15 to $7.11. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.